Generalized Anxiety Disorder (GAD) affects about 2.7% of U.S. adults over 12 months, and around 3.6% worldwide each year. It’s more often diagnosed in women than men (2:1) and commonly begins between ages 20–30 in 50% of cases. GAD also overlaps with major depression, panic disorder, social anxiety disorder, and some substance use disorders—so care plans may need to address more than anxiety alone. Explore the U.S. economic and symptom-impact data, plus evidence-based options like CBT, SSRIs, benzodiazepines, and mindfulness.
Key Takeaways
- GAD comorbidity with major depression occurs in 59% of cases
- 38% of GAD patients also have panic disorder
- GAD co-occurs with social anxiety disorder in 42% of individuals
- Women are twice as likely as men to be diagnosed with GAD, with a female-to-male ratio of 2:1
- GAD onset typically occurs between ages 20-30 years in 50% of cases
- Among U.S. adults aged 18-29, GAD prevalence is 4.9%
- Annual economic cost of GAD in the U.S. is $42 billion in healthcare and lost productivity
- GAD leads to 25 million lost workdays annually in the U.S.
- Average annual healthcare cost for GAD patient is $4,800 higher than non-GAD
- The 12-month prevalence of Generalized Anxiety Disorder (GAD) among U.S. adults aged 18 and older is 2.7%
- Lifetime prevalence of GAD in the U.S. adult population is approximately 5.7%
- Globally, GAD affects about 3.6% of the population annually
- Cognitive Behavioral Therapy (CBT) remission rate for GAD is 50-60% after 12 sessions
- SSRIs like sertraline achieve 55% response rate in GAD over 8 weeks
- Benzodiazepines provide 70% acute relief but only 30% long-term for GAD
Generalized anxiety disorder affects about 3.6% globally and often overlaps with depression, costing the US $42 billion yearly.
Related reading
01 · Category
Comorbidity30 stats
01
GAD comorbidity with major depression occurs in 59% of cases
02
38% of GAD patients also have panic disorder
03
GAD co-occurs with social anxiety disorder in 42% of individuals
04
Substance use disorders are present in 22% of GAD cases
05
PTSD comorbidity with GAD is 28% among trauma-exposed
06
52% of GAD sufferers have specific phobia comorbidity
07
Bipolar disorder co-occurs with GAD in 18% of cases
08
Chronic pain conditions accompany GAD in 35% of patients
09
OCD comorbidity rate with GAD is 24%
10
GAD and agoraphobia co-occur in 15% of anxiety cases
11
67% of GAD cases have at least one other anxiety disorder
12
Alcohol dependence in 20% of lifetime GAD patients
13
GAD with dysthymia in 30% of persistent cases
14
Cardiovascular disease risk increases 1.5-fold with GAD comorbidity
15
41% of GAD patients have personality disorder traits
16
Eating disorders co-occur with GAD in 12% of females
17
GAD and ADHD comorbidity is 19% in adults
18
Sleep disorders present in 55% of GAD cases
19
Irritable bowel syndrome with GAD in 25% of GI patients
20
Schizophrenia comorbidity with GAD is 14%
21
Migraine headaches co-occur with GAD in 32%
22
Diabetes mellitus type 2 with GAD raises in 27% cases
23
48% of GAD have generalized social phobia overlap
24
Opioid use disorder in 16% of chronic GAD patients
25
Asthma exacerbation linked to GAD in 29%
26
Borderline personality disorder with GAD in 23%
27
Fibromyalgia comorbidity rate is 31% with GAD
28
GAD and separation anxiety persist in 17% adults
29
Nicotine dependence in 37% of GAD smokers
30
65% of severe GAD have multiple comorbidities
Interpretation
Comorbidity Interpretation
From a comorbidity perspective, GAD commonly clusters with other anxiety and trauma related conditions, with major depression present in 59% of cases and social anxiety disorder and specific phobia occurring in 42% and 52% respectively.
02 · Category
Demographics27 stats
01
Women are twice as likely as men to be diagnosed with GAD, with a female-to-male ratio of 2:1
02
GAD onset typically occurs between ages 20-30 years in 50% of cases
03
Among U.S. adults aged 18-29, GAD prevalence is 4.9%
04
In older adults (65+), women have 2.5% GAD prevalence vs. 1.2% for men
05
U.S. Black adults have a GAD lifetime prevalence of 4.9%
06
Among Asian Americans, GAD 12-month prevalence is 1.6%
07
U.S. adults with less than high school education show 5.1% GAD prevalence
08
Married U.S. adults have 2.1% GAD rate vs. 3.8% for never married
09
Among U.S. urban residents, GAD prevalence is 3.0% vs. 2.4% rural
10
U.S. adults aged 45-64 have 3.1% 12-month GAD prevalence
11
Hispanic women in U.S. have 5.8% GAD lifetime risk
12
Among U.S. high-income earners, GAD prevalence is 1.8%
13
GAD is more common in divorced/separated U.S. adults at 4.5%
14
U.S. Native American adults have 3.9% GAD prevalence
15
Among college-educated U.S. adults, GAD rate is 2.3%
16
U.S. adults aged 30-44 show 3.4% GAD prevalence
17
White U.S. adults have 3.6% lifetime GAD vs. 2.1% for Asians
18
Among U.S. unemployed adults, GAD prevalence is 6.2%
19
GAD onset after age 50 occurs in only 15% of cases
20
U.S. multiracial adults have 4.2% GAD prevalence
21
Among U.S. adults with children under 18, GAD is 3.5%
22
Low SES U.S. women have 6.8% GAD rate
23
U.S. Pacific Islander adults show 2.7% GAD prevalence
24
GAD is diagnosed in 2.8% of U.S. adults aged 65+
25
60% of GAD cases in U.S. have onset before age 25
26
U.S. men in urban areas have 2.0% GAD prevalence
27
Among U.S. immigrants, GAD prevalence is 3.9%
Interpretation
Demographics Interpretation
From a demographics perspective, GAD affects women more than men, with women diagnosed at a 2 to 1 ratio and later-life prevalence at 2.5% versus 1.2% for men, while onset in half of cases typically begins between ages 20 and 30.
03 · Category
Economic Burden26 stats
01
Annual economic cost of GAD in the U.S. is $42 billion in healthcare and lost productivity
02
GAD leads to 25 million lost workdays annually in the U.S.
03
Average annual healthcare cost for GAD patient is $4,800higher than non-GAD
04
Workplace absenteeism due to GAD costs U.S. employers $11 billion yearly
05
Global economic burden of GAD is estimated at $1 trillion in lost productivity
06
GAD increases disability-adjusted life years (DALYs) by 1.4 million globally
07
U.S. GAD patients have 2.3 times higher medical utilization costs
08
Presenteeism from GAD reduces productivity by 15-20% daily
09
Lifetime excess cost per GAD case in Europe is €25,000
10
GAD-related emergency visits cost U.S. $2.5 billion annually
11
Suicide attempt risk in GAD raises healthcare costs by 40%
12
U.S. pharmaceutical spending on GAD meds is $3.1 billion yearly
13
GAD contributes to 5.6% of all disability in high-income countries
14
Long-term sick leave for GAD averages 120 days per year in EU
15
U.S. indirect costs (lost wages) for GAD total $28 billion annually
16
GAD increases workers' compensation claims by 2.5-fold
17
Annual GDP loss from GAD in Australia is AUD 2.5 billion
18
Hospitalization rates for GAD comorbidities add $10 billion U.S. costs
19
GAD reduces life expectancy by 2-3 years via comorbidities, impacting pension costs
20
U.S. primary care visits for GAD cost $1.2 billion per year
21
Disability benefits for GAD claim 8% of mental health payouts in UK
22
GAD-linked turnover costs U.S. businesses $5 billion annually
23
Per capita economic burden of GAD in U.S. is $1,200yearly
24
Early intervention saves $4,500per GAD case in lifetime costs
25
GAD contributes to 3% of total mental health spending globally
26
U.S. veteran GAD care costs VA $1.8 billion annually
Interpretation
Economic Burden Interpretation
The economic burden of GAD is substantial, with the U.S. losing $42 billion annually in healthcare and productivity and another $11 billion in employer absenteeism while global productivity losses reach an estimated $1 trillion and add 1.4 million DALYs worldwide.
04 · Category
Prevalence30 stats
01
The 12-month prevalence of Generalized Anxiety Disorder (GAD) among U.S. adults aged 18 and older is 2.7%
02
Lifetime prevalence of GAD in the U.S. adult population is approximately 5.7%
03
Globally, GAD affects about 3.6% of the population annually
04
In Europe, the 12-month GAD prevalence is 1.7% among adults
05
GAD point prevalence in primary care settings is 8.1%
06
Among U.S. adolescents (13-18 years), lifetime GAD prevalence is 6.1%
07
In Australia, 5.9% of adults experience GAD over 12 months
08
GAD prevalence among U.S. community samples is 4.0% for lifetime risk
09
In the UK, 5.4% of adults report GAD symptoms meeting diagnostic criteria annually
10
Among older U.S. adults (65+), GAD prevalence is 1.9% over 12 months
11
In Canada, 2.6% of the population aged 15+ has GAD in the past year
12
GAD affects 3.2% of primary care patients worldwide
13
U.S. military veterans have a 10.9% 12-month GAD prevalence
14
In Japan, GAD lifetime prevalence is 2.6%
15
Among U.S. college students, GAD prevalence is 11.6%
16
In Brazil, 9.3% of the population meets GAD criteria over 12 months
17
GAD 12-month prevalence in New Zealand is 2.2%
18
Among U.S. Hispanics, GAD lifetime prevalence is 7.0%
19
In India, community GAD prevalence is 5.8%
20
U.S. women have a 12-month GAD prevalence of 4.3% vs. 2.2% for men
21
GAD prevalence among U.S. adults with chronic illness is 7.7%
22
In South Africa, GAD affects 2.6% of adults annually
23
Among U.S. low-income adults, GAD prevalence reaches 9.2%
24
In Germany, GAD lifetime risk is 4.0%
25
U.S. rural adults show 3.1% GAD prevalence
26
In China, urban GAD prevalence is 5.0%
27
Among U.S. postpartum women, GAD incidence is 10.5%
28
GAD prevalence in U.S. prisons is 15.4%
29
In Sweden, 2.4% of adults have GAD annually
30
GAD among U.S. LGBTQ+ adults is 12.7%
Interpretation
Prevalence Interpretation
From a prevalence perspective, generalized anxiety disorder is relatively common, with about 2.7% of U.S. adults experiencing it within the past 12 months and 5.7% at some point over their lifetime, and these rates rise even further in primary care where point prevalence reaches 8.1%.
05 · Category
Treatment28 stats
01
Cognitive Behavioral Therapy (CBT) remission rate for GAD is 50-60% after 12 sessions
02
SSRIs like sertraline achieve 55% response rate in GAD over 8 weeks
03
Benzodiazepines provide 70% acute relief but only 30% long-term for GAD
04
Mindfulness-Based Stress Reduction (MBSR) reduces GAD symptoms by 38% in 8 weeks
05
SNRIs such as venlafaxine show 60% efficacy in GAD treatment trials
06
Internet-delivered CBT for GAD has 45% remission rate
07
Pregabalin reduces Hamilton Anxiety Rating Scale scores by 12.3 points in GAD
08
Group CBT for GAD yields 52% improvement vs. 32% waitlist
09
Buspirone monotherapy response in GAD is 48% at 6 weeks
10
Acceptance and Commitment Therapy (ACT) reduces GAD worry by 40%
11
Combined CBT + medication remission for GAD is 65%
12
Duloxetine achieves 58% response in generalized anxiety
13
Exercise intervention lowers GAD-7 scores by 25% weekly
14
Hydroxyzine shows 51% responder rate in short-term GAD trials
15
Long-term CBT maintenance prevents GAD relapse in 70% cases
16
Escitalopram reduces GAD symptoms by 50% in 12 weeks
17
Yoga practice decreases GAD severity by 35% over 10 weeks
18
Paroxetine efficacy in GAD is 54% vs. placebo 32%
19
Psychodynamic therapy for GAD shows 42% improvement rate
20
Gabapentin adjunct therapy improves GAD by 28% additional
21
Digital therapeutics for GAD achieve 47% symptom reduction
22
Fluoxetine response rate in GAD is 52%
23
Biofeedback training lowers GAD anxiety by 33%
24
Riluzole as adjunct reduces GAD symptoms in 40% refractory cases
25
Family therapy for GAD improves outcomes by 55%
26
Vortioxetine shows 59% response in GAD phase III trials
27
Tai Chi reduces GAD severity scores by 30%
28
Only 37.1% of U.S. adults with GAD receive any treatment
Interpretation
Treatment Interpretation
For Gad treatment, the most consistent trend is that structured therapy and antidepressant options tend to produce moderate to strong symptom improvements within weeks, with CBT remission in the 45 to 60 percent range and SSRIs delivering about a 55 percent response over 8 weeks.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Helena Kowalczyk. (2026, February 13). Gad Statistics. Gitnux. https://gitnux.org/gad-statistics
MLA
Helena Kowalczyk. "Gad Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/gad-statistics.
Chicago
Helena Kowalczyk. 2026. "Gad Statistics." Gitnux. https://gitnux.org/gad-statistics.
Sources & references
16 datasets cited across this report · attribution is report-level